EUROPEAN NEUROPSYCHOPHARMACOLOGY

metrics 2024

Illuminating Pathways to Effective Therapies

Introduction

EUROPEAN NEUROPSYCHOPHARMACOLOGY, published by Elsevier, is a prestigious academic journal that serves as a cornerstone in the field of neuropsychopharmacology, embracing multidisciplinary research at the intersection of neuroscience, psychiatry, and pharmacology. Since its establishment in 1990, this journal has consistently delivered cutting-edge research and reviews that drive forward our understanding of central nervous system disorders and their treatment. With an impressive impact factor and ranked in the Q1 category for several disciplines, including Biological Psychiatry and Neurology, it attracts submissions from leading researchers globally. The journal’s Scopus rankings reflect its significant influence, ranking in the top echelons across various categories such as Medicine and Neuroscience. While the journal maintains subscription access, readers are encouraged to explore the breadth of important findings that contribute to advancements in treatment options and improve patient care. EUROPEAN NEUROPSYCHOPHARMACOLOGY not only supports the dissemination of pivotal research but also fosters collaboration and dialogue within the scientific community, making it an essential resource for researchers, clinicians, and students dedicated to the complexities of brain health.

Metrics 2024

SCIMAGO Journal Rank1.76
Journal Impact Factor6.10
Journal Impact Factor (5 years)5.30
H-Index130
Journal IF Without Self6.10
Eigen Factor0.01
Normal Eigen Factor1.92
Influence1.74
Immediacy Index2.00
Cited Half Life7.60
Citing Half Life7.30
JCI1.27
Total Documents3104
WOS Total Citations8533
SCIMAGO Total Citations36218
SCIMAGO SELF Citations1069
Scopus Journal Rank1.76
Cites / Document (2 Years)4.22
Cites / Document (3 Years)4.52
Cites / Document (4 Years)4.52

Metrics History

Rank 2024

Scopus

Pharmacology (medical) in Medicine
Rank #17/272
Percentile 93.75
Quartile Q1
Psychiatry and Mental Health in Medicine
Rank #47/567
Percentile 91.71
Quartile Q1
Neurology in Neuroscience
Rank #18/192
Percentile 90.62
Quartile Q1
Neurology (clinical) in Medicine
Rank #37/400
Percentile 90.75
Quartile Q1
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #33/313
Percentile 89.46
Quartile Q1
Biological Psychiatry in Neuroscience
Rank #8/51
Percentile 84.31
Quartile Q1

IF (Web Of Science)

CLINICAL NEUROLOGY
Rank 22/277
Percentile 92.20
Quartile Q1
NEUROSCIENCES
Rank 33/310
Percentile 89.50
Quartile Q1
PHARMACOLOGY & PHARMACY
Rank 26/354
Percentile 92.80
Quartile Q1
PSYCHIATRY
Rank 21/276
Percentile 92.60
Quartile Q1

JCI (Web Of Science)

CLINICAL NEUROLOGY
Rank 49/278
Percentile 82.37
Quartile Q1
NEUROSCIENCES
Rank 61/310
Percentile 80.32
Quartile Q1
PHARMACOLOGY & PHARMACY
Rank 46/354
Percentile 87.01
Quartile Q1
PSYCHIATRY
Rank 45/276
Percentile 83.70
Quartile Q1

Quartile History

Similar Journals

NERVENARZT

Advancing the Frontiers of Neurology and Psychiatry
Publisher: SPRINGERISSN: 0028-2804Frequency: 12 issues/year

NERVENARZT, published by Springer, has established itself as a significant platform in the fields of Medicine, Neurology, and Psychiatry since its inception in 1947. With a focus on a wide array of topics in neurological and psychiatric health, the journal plays a crucial role in disseminating cutting-edge research and clinical insights that enhance understanding and treatment of neurological disorders. The journal is currently positioned in the Q3 category across various fields, reflecting its role in the academic community, and provides valuable contributions to both the clinical and theoretical aspects of neurology and psychiatry. While it does not offer open access options, NERVENARZT continues to make significant strides in literature with its comprehensive articles and research findings, aimed at researchers, healthcare professionals, and students interested in the latest developments in the neuroscience and mental health landscapes. Operating under rigorous academic standards, it holds respected rankings with Scopus, further underscoring its commitment to impactful scholarship through the years.

Psychiatry International

Advancing global mental health research.
Publisher: MDPIISSN: Frequency: 4 issues/year

Psychiatry International, published by MDPI, is a dynamic and open-access journal dedicated to advancing the field of psychiatry and mental health. Since its inception in 2020, this journal has emerged as a vital platform for the dissemination of innovative research and impactful insights across various subdisciplines, encompassing psychiatric nursing, general medicine, and neuroscience. With an E-ISSN of 2673-5318, Psychiatry International facilitates accessibility to research findings and fosters collaboration among researchers, healthcare professionals, and academics worldwide. The journal's alignment with modern Open Access principles reflects its commitment to enhancing the visibility and reach of psychiatric research. Despite being relatively new, it has demonstrated a promising standing in Scopus rankings, positioning itself within the top quartile for Nursing (Psychiatric Mental Health) and showing potential for growth in other related categories. By encouraging submissions that address the latest developments and challenges in mental health, Psychiatry International aims to catalyze progress in mental health awareness and intervention strategies, making it an essential resource for anyone engaged in the field.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Charting New Territories in Neuropsychopharmacological Science
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0278-5846Frequency: 8 issues/year

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

Neuropsychopharmacology Reports

Enhancing well-being with cutting-edge neuropsychopharmacology insights.
Publisher: WILEYISSN: Frequency: 4 issues/year

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.

NeuroImage-Clinical

Transforming Clinical Practice through Cutting-edge Research
Publisher: ELSEVIER SCI LTDISSN: 2213-1582Frequency:

NeuroImage-Clinical is a premier open access journal published by Elsevier Science Ltd, dedicated to advancing the field of clinical neuroimaging and its applications in a variety of neurological disorders. With an ISSN of 2213-1582, this journal has established itself as a leading source of innovative research since its inception in 2012, now continuing through 2024. Recognized for its high impact, it occupies the top quartile (Q1) in prestigious categories such as Cognitive Neuroscience, Neurology, and Radiology, affirming its relevance in clinical and research settings. Its Scopus rankings further exemplify its significant contribution to the disciplines of Radiology and Neurology, consistently placing it among the top tiers of journals in these fields. This journal not only provides critical insights for researchers and professionals but also serves as a valuable resource for students, fostering an understanding of the complexities in neuroimaging techniques and their implications for patient care. With open access options ensuring broad dissemination of knowledge, NeuroImage-Clinical plays a pivotal role in enhancing collaboration and innovation within the global neuroscience community.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Illuminating the path to better psychiatric therapies.
Publisher: OXFORD UNIV PRESSISSN: 1461-1457Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, published by OXFORD UNIV PRESS, is a leading open-access journal in the fields of pharmacology and psychiatry, with an impressive impact factor reflecting its prominence in academic research. Since its inception in 1998, the journal has provided a crucial platform for the publication of high-quality research, offering insights into the effects of neuropharmacological agents on mental health. As of 2023, it ranks in the Q1 category for both Pharmacology and Psychiatry & Mental Health, underscoring its relevance and authority within the scientific community. With notable rankings in various medical subspecialties, it attracts contributions that advance our understanding of psychiatric disorders and therapeutic strategies. The accessible nature of the journal, following its transition to open access in 2015, has expanded its reach, making knowledge and findings readily available to researchers, professionals, and students globally. This commitment to disseminating impactful research ensures the journal remains at the forefront of neuropsychopharmacological advancements.

NEUROPSYCHOPHARMACOLOGY

Pioneering Research at the Intersection of Psychiatry and Pharmacology
Publisher: SPRINGERNATUREISSN: 0893-133XFrequency: 13 issues/year

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

Biological Psychiatry-Cognitive Neuroscience and Neuroimaging

Illuminating the Pathways of Cognitive Neuroscience
Publisher: ELSEVIERISSN: 2451-9022Frequency: 12 issues/year

Biological Psychiatry-Cognitive Neuroscience and Neuroimaging is a leading interdisciplinary journal published by Elsevier, focusing on the convergence of biological psychiatry, cognitive neuroscience, and advanced neuroimaging techniques. With its prestigious Q1 rankings across essential categories such as Biological Psychiatry, Cognitive Neuroscience, and Neurology (clinical), this journal is at the forefront of research that examines the complexities of mental health through innovative methodologies. Covering a broad spectrum of topics from neurobiological mechanisms to clinical applications, it aims to provide a platform for scholars and practitioners to exchange insights on mental disorders and their neurobiological underpinnings. The impact factor and Scopus rankings further underscore its importance, with rankings highlighting its position in the top percentiles of related disciplines. By fostering an open exchange of ideas and promoting cutting-edge research, this journal is an essential resource for researchers, professionals, and students dedicated to advancements in the understanding and treatment of psychiatric and neurological conditions.

CORTEX

Exploring the Frontiers of Cognitive Neuroscience
Publisher: ELSEVIER MASSON, CORP OFFISSN: 0010-9452Frequency: 10 issues/year

CORTEX is a premier international journal published by Elsevier Masson, focusing on the cutting-edge areas of cognitive neuroscience, psychology, and neurology. With an impressive impact factor that places it in Q1 quartiles across multiple categories such as Cognitive Neuroscience and Neuropsychology, this journal serves as a vital resource for researchers, clinicians, and students alike. Established in 1964, CORTEX has continued to excel in disseminating high-quality scholarly work, offering insights that significantly enhance our understanding of the brain's functioning and behavior. Although not an open-access publication, it provides various access options to ensure the dissemination of knowledge is as wide-reaching as possible. As the field of cognitive psychology evolves, CORTEX remains at the forefront, fostering an environment for interdisciplinary collaboration and innovation. Researchers seeking to stay engaged with the latest advancements will find CORTEX an indispensable tool for their professional development.

PSYCHIATRY RESEARCH-NEUROIMAGING

Pioneering Research at the Intersection of Mind and Machine
Publisher: ELSEVIER IRELAND LTDISSN: 0925-4927Frequency: 12 issues/year

PSYCHIATRY RESEARCH-NEUROIMAGING, published by Elsevier Ireland Ltd, stands at the intersection of neuroscience, psychiatry, and medical imaging, specializing in the latest advancements in neuroimaging techniques and their applications in psychiatric research. With a robust history since 1990, this esteemed journal features original research, reviews, and case studies that contribute significantly to the understanding of brain function in mental health disorders. Holding a notable Impact Factor and classified in Q2 for the fields of Neuroscience and Psychiatry and Q1 for Radiology, it serves as a vital resource for scholars and practitioners seeking to advance their knowledge in these domains. The journal is indexed in major databases, enhancing visibility and accessibility for global researchers. While it currently does not follow an open-access model, its reputable standing in Scopus ranks, alongside its targeted scope, makes it indispensable for those invested in neuroimaging research and its implications in psychiatry.